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Serotonin is a highly ubiquitous signaling molecule that plays a role in the regulation of various
physiological functions. Several lines of evidence, including the present work from Hsiao and col-
leagues, demonstrate that, in the gut, microbial-derived metabolites affect the production of sero-
tonin that in turn impacts host physiological functions.The body’s epithelial surfaces act as a
scaffold to sustain diverse communities
of commensals that include bacteria,
archaea, fungi, protozoa, and virus.
Although the notion that these microbial
partners can promote human health is
not a recent concept, the extent to which
the microbiota controls all physiological
systems has only recently begun to be
appreciated. Of particular interest are the
recent lines of investigation linking the mi-
crobiota toboth thehormonal andnervous
systems. In this context, a set of recent
findings, including the work of Hsiao and
colleagues, uncovers a role for the micro-
biota in controlling the production of a
major neurotransmitter, serotonin.
In 1967, Abrams and Bishop showed
that animals devoid of live microbes
(germ-free) had decreased gut motility
compared to animals harboring a con-
ventional mouse microbiota (Abrams
and Bishop, 1967). Decreased serotonin
levels in the absence of microbes have
been proposed as a potential cause for
this defect (Wikoff et al., 2009; Kashyap
et al., 2013). Serotonin is a highly ubiqui-
tous signaling molecule that plays a
fundamental role in the regulation of
various physiological functions via its ac-
tion as both a neurotransmitter and a hor-
mone. The vast majority of serotonin is
produced in the gut by enterochromaffin
cells, a specialized subset of cells strate-
gically positioned to respond to chemical
and mechanical stimuli (Figure 1). As a
single molecule, serotonin has a remark-
ably wide range of effects on host physi-
ology, ranging from the control of gut
motility, secretory reflexes, platelet ag-gregation, bone development, and car-
diac function to the regulation of immune
responses (Mawe and Hoffman, 2013).
Germ-free mice display depressed levels
of this neurotransmitter compared to
conventionally raised animals (Wikoff
et al., 2009). Colonization of germ-free
animals with the gut microbiota from
humans or mice can significantly accel-
erate gut transit time, an effect that can
be partially blocked using a pharmaco-
logic antagonist of a serotonin receptor
(Kashyap et al., 2013).
In the present issue of Cell, the work of
Yano et al. (2015), together with previous
lines of evidence, proposes a model
in which microbial-derived metabolites,
such as short-chain fatty acids (i.e., buty-
rate and acetate) or secondary bile acids
(specifically deoxycolate), directly act
upon enterochromaffin cells (ECs),
inducing transcription of the rate-limiting
serotonin biosynthetic enzyme thp1
(Yano et al., 2015; Fukumoto et al.,
2003; Reigstad et al., 2014; Figure 1). A
link between microbiota-derived meta-
bolic products and enterochromaffin cell
function has been previously reported by
Reigstad et al., where they propose that
short-chain fatty acids canmodulate tran-
scription of Chga gene, which encodes
the neuroendocrine secretory protein
chromogranin A, released together with
serotonin (Figure 1). These results were
corroborated by Yano et al. and corre-
lated, in treated mice, with decreased
transit time. Further, via increase in sero-
tonin production, the presence of the mi-
crobiota was associated with increased
platelet activation and aggregation, find-Celings that help to explain the improved
coagulation at the site of injury in animals
harboring a gut microbiota compared to
germ-free mice. Of interest is the diversity
of microbial-derived metabolites that can
increase serotonin production, support-
ing the idea that the mechanisms control-
ling this brain-gut interaction are redun-
dant and are unlikely to be affected by
subtle microbial shifts. Because of the
fundamental importance of serotonin in
mediating central body functions, such
redundancy may have been maintained
as a means to sustain the production of
this neurotransmitter in the face of consti-
tutive microbial fluctuation. Nonetheless,
not all microbes are equally efficient at
promoting serotonin production. Yano
et al. correlated the localized changes of
serotonin with the presence of spore-
forming bacteria, primarily from the Clos-
tridium genus. Given the diversity of
microbially derived metabolites, it is un-
likely that a defined microbe will be asso-
ciated with this effect. The mechanism by
which the microbiota promotes serotonin
production and, in particular, if and how
enterochromaffin cells directly respond
to microbiota-derived products and me-
tabolites remain unclear. Furthermore,
the systemic effects of this control on
distal tissues and peripheral function are
still unknown.
Of interest, and yet to be studied, is the
effect that increased serotonin may have
on the ecology and metabolism of the
gut microbiota (Figure 1). Serotonin can
act directly or indirectly on the immune
system, which in turn can shape the
microbiota composition and localization.l 161, April 9, 2015 ª2015 Elsevier Inc. 193
Figure 1. Role of the Microbiota in Serotonin Production
The gut microbiota influences the number and function of enterochromaffin cells, thereby promoting the
release of serotonin (5-HT). The microbiota promotes serotonin production via various metabolites,
including short-chain fatty acid (SCFA). Serotonin can act on various physiological systems promoting gut
motility, secretory reflexes, and platelet function. The action of serotonin can be local as well as distal (on
bone development and cardiac function) via platelet-mediated transport. Serotonin can also influence the
immune system, an effect that could feed back on enterochromaffin cells and themicrobiota itself. Defined
microbes have also been shown to produce serotonin, a pathway that may further link the microbiota and
host serotonin levels.The feedback loop associated with this
control remains to be explored. Micro-
bially induced changes in serotonin con-
centrations may regulate the host’s
immune response and may subsequently
influence how the host deals with patho-
gens or commensals. Of interest, defined
microbes themselves can produce sero-
tonin (O’Mahony et al., 2015); this raises
the question of whether serotonin can
play a direct role in microbial metabolism
or in the maintenance of the ecological
niche of certain phylogenetic groups
(i.e., spore-forming bacteria).194 Cell 161, April 9, 2015 ª2015 Elsevier IncAn important line of future investigation
will be to explore how microbiota control
of serotonin levels contributes to mucosal
disorders, a question of particular impor-
tance because of the known role of
serotonin in promoting immunity and
inflammation. Of interest, in various
models of mucosal inflammation or infec-
tions, as well as in Celiac disease pa-
tients, serotonin levels are significantly
increased (Mawe and Hoffman, 2013).
Further, both antagonists and agonists
to the serotonin receptor have been
used to clinically treat a variety of gastro-.intestinal disorders (Manocha and Khan,
2012). Based on the present findings,
further understanding of the mechanism
by which the microbiota regulates host’s
serotonin levels may be a first step toward
developing pro- and/or prebiotic strate-
gies to complement or potentially replace
existing clinical treatments.ACKNOWLEDGMENTS
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